Skip header and navigation

6 records – page 1 of 1.

The AIDS epidemic in Sweden: estimates of costs, 1986, 1987 and 1990.

https://arctichealth.org/en/permalink/ahliterature8546
Source
Scand J Soc Med. 1989;17(1):39-48
Publication Type
Article
Date
1989
Author
C. Herlitz
B. Brorsson
Author Affiliation
Dalarna Research Council, Falun, Sweden.
Source
Scand J Soc Med. 1989;17(1):39-48
Date
1989
Language
English
Publication Type
Article
Keywords
AIDS Serodiagnosis - economics
Acquired Immunodeficiency Syndrome - economics - therapy
Costs and Cost Analysis
Disease Outbreaks - economics
Forecasting
Health Expenditures
Humans
Research Support, Non-U.S. Gov't
Sweden
Abstract
This study calculates the cost of medical care during the different stages of HIV infection, from the asymptomatic period to a confirmed AIDS diagnosis. Also, we have estimated the total cost of taking specimens and performing tests related to HIV infection, and the cost of information, research, etc. Medical costs were based on estimates of the average cost per day and the total number of days at the various stages of HIV infection. The cost estimates for testing include costs related to taking specimens, analysing samples, managing test results, etc. The cost outlook until 1990 is discussed using different assumptions concerning incidence, survival and the level of preventive efforts. The total estimated costs for medical care, HIV tests, information, etc. doubled between 1986 and 1987. During 1987, costs totaled 313 million Swedish kronor (SEK). The costs for specimens and tests totaled SEK 124 million, medical costs for HIV positives who had not developed AIDS totaled SEK 31 million, and medical costs for AIDS patients totaled SEK 26 million. The costs discussed in this study will probably increase by at least 50% by 1990.
PubMed ID
2496463 View in PubMed
Less detail

Canada contribute to the '3 by 5' AIDS treatment initiative.

https://arctichealth.org/en/permalink/ahliterature177954
Source
Expert Rev Anti Infect Ther. 2004 Jun;2(3):341
Publication Type
Article
Date
Jun-2004
Source
Expert Rev Anti Infect Ther. 2004 Jun;2(3):341
Date
Jun-2004
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - economics - therapy
Canada
Humans
International Cooperation
World Health Organization
PubMed ID
15482198 View in PubMed
Less detail

The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

https://arctichealth.org/en/permalink/ahliterature184385
Source
CMAJ. 2003 Jul 22;169(2):106-10
Publication Type
Article
Date
Jul-22-2003
Author
Hartmut B Krentz
M Christopher Auld
M John Gill
Author Affiliation
Southern Alberta HIV/AIDS Clinic and the Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB. Harmut.Krentz@CalgaryHealthRegion.ca
Source
CMAJ. 2003 Jul 22;169(2):106-10
Date
Jul-22-2003
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - economics - therapy
Adult
Alberta
Ambulatory Care - economics
Anti-HIV Agents - economics
Antiretroviral Therapy, Highly Active - economics
Female
HIV Infections - drug therapy - economics
Health Care Costs
Home Care Services - economics
Hospital Costs
Humans
Male
Universal Coverage - economics
Abstract
Determining the direct cost of providing medical care to patients with HIV/AIDS is important for both short-term and long-term decision-making and for appropriate resource allocation. We aimed to categorize and measure the direct costs of medical care provided to the entire HIV-positive population receiving care in southern Alberta between 1995 and 2001.
We collected all patient-specific direct costs including the cost of pharmaceutical drugs (HIV and non-HIV drugs), outpatient care (including physician costs and laboratory testing), inpatient (in-hospital) care and home care (acute, long-term, palliative) from primary sources for all patients between April 1995 and April 2001. We determined cost per patient per month (PPPM) adjusted to 2001 Canadian dollars.
Since 1995, the direct cost of providing medical care to patients with HIV/AIDS has increased primarily as a result of increased antiretroviral drug costs both in absolute and in PPPM terms. Mean PPPM expenditures increased from 655 Canadian dollars in 1995/96, that is, before the use of highly active antiretroviral therapy (HAART), to 1036 Canadian dollars in 1997/98 when HAART was widely used. During the following 3 years, mean overall PPPM costs remained stable. Antiretroviral drugs accounted for 30% (198 Canadian dollars PPPM) of the total cost in 1995/96 increasing to 69% (775 Canadian dollars PPPM) in 2000/01. Inpatient, outpatient and home care costs decreased in both percentage and cost PPPM between 1995/96 and 2000/01 from 26% to 10%, 27% to 14% and 8% to 3% respectively.
The cost of providing medical care to HIV-positive patients continues to increase, although the burden of costs is distributed differently from before the introduction of HAART, with the costs of drug therapy offsetting the costs of inpatient care and home care. Careful consideration of all aspects of direct costing data is needed when any health economic policy issues are examined.
Notes
Cites: N Engl J Med. 2001 Mar 15;344(11):817-2311248159
Cites: AIDS Patient Care STDS. 2001 Jan;15(1):25-911177585
Cites: J Med Syst. 2001 Feb;25(1):73-8011288483
Cites: J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-911404515
Cites: Pharmacoeconomics. 2001;19(7):709-1311548908
Cites: AIDS Care. 2001 Dec;13(6):721-3111720642
Cites: Nihon Rinsho. 2002 Apr;60(4):813-611968794
Cites: Health Econ. 2002 Dec;11(8):735-912457373
Cites: Health Policy. 1993 Apr;24(1):55-7010125812
Cites: Pharmacoeconomics. 1998 Mar;13(3):327-3610178658
Cites: Pharmacoeconomics. 1999;15 Suppl 1:1-1210537438
Cites: AIDS. 1999 May 28;13(8):963-910371178
Cites: AIDS. 1999 Jun 18;13(9):1115-2210397543
Comment In: CMAJ. 2003 Jul 22;169(2):120-112874159
PubMed ID
12874156 View in PubMed
Less detail

HIV antibody screening among immigrants: a cost-benefit analysis.

https://arctichealth.org/en/permalink/ahliterature228707
Source
CMAJ. 1990 Jul 15;143(2):101-7
Publication Type
Article
Date
Jul-15-1990
Author
H. Zowall
R D Fraser
N. Gilmore
A. Deutsch
S. Grover
Author Affiliation
Division of Clinical Epidemiology, Montreal General Hospital, PQ.
Source
CMAJ. 1990 Jul 15;143(2):101-7
Date
Jul-15-1990
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - economics - therapy
Blotting, Western
Canada - epidemiology
Cost-Benefit Analysis
Delivery of Health Care - economics
Emigration and Immigration - statistics & numerical data
Enzyme-Linked Immunosorbent Assay
Female
HIV Antibodies - analysis
HIV Seropositivity - diagnosis - economics
HIV Seroprevalence
Humans
Male
Mass Screening - economics
Predictive value of tests
Abstract
To assess the economic impact of HIV (human immunodeficiency virus) antibody screening among potential immigrants on Canada's health care system we estimated the costs and benefits of such screening among the 160 135 immigrants who entered Canada in 1988 using the in-hospital costs of treating AIDS (acquired immune deficiency syndrome) over the 10 years after immigration. This economic model was based on current international HIV seroprevalence data, Canadian immigration statistics and estimates of disease progression. Between 343 and 862 of the immigrants were estimated to have been HIV seropositive; with the use of the enzyme-linked immunosorbent assay and the Western blot technique 310 to 780 of them would have been correctly identified as being seropositive, and 33 to 82 would have been incorrectly classified as being seronegative. Another 16 would have been falsely classified as being seropositive. There would have been 151 to 379 cases of AIDS from 1988 to 1998 among the immigrants identified as being HIV-positive. The estimated total cost of screening would have been $3.3 to $3.4 million. The in-hospital costs of treating HIV-infected immigrants in whom AIDS developed between 1989 and 1998 would have been $5.0 to $17.1 million. Accordingly, screening would have saved $1.7 to $13.7 million over the 10 years after immigration. However, we do not advocate screening on the basis of economic analysis alone and acknowledge that any policy regarding such screening must also incorporate social, legal and ethical considerations.
Notes
Cites: JAMA. 1987 Oct 2;258(13):1757-623476759
Cites: Science. 1988 Feb 5;239(4840):573-93277271
Cites: Science. 1988 Feb 5;239(4840):610-63340847
Cites: West J Med. 1987 Dec;147(6):719-223433756
Cites: West J Med. 1987 Dec;147(6):723-53433757
Cites: West J Med. 1987 Dec;147(6):726-93433758
Cites: JAMA. 1986 Nov 7;256(17):2343-43464767
Cites: Am J Public Health. 1988 Apr;78(4):450-43126676
Cites: S Afr Med J. 1988 Apr 16;73(8):461-43282332
Cites: J Acquir Immune Defic Syndr. 1988;1(5):466-853065476
Cites: N Engl J Med. 1989 Jun 1;320(22):1487-92716799
Cites: Am J Infect Control. 1989 Aug;17(4):213-252672903
Cites: Lancet. 1987 Jul 18;2(8551):1662885635
Cites: JAMA. 1987 Jul 3;258(1):46-73586289
Cites: Science. 1987 May 15;236(4803):827-313033826
Cites: Lancet. 1987 Feb 21;1(8530):408-112880215
Cites: Acta Haematol. 1988;79(2):91-33124480
Cites: N Engl J Med. 1978 Oct 26;299(17):926-30692598
Cites: Can Med Assoc J. 1981 Sep 1;125(5):415-6, 4507284923
Cites: JAMA. 1985 Nov 8;254(18):2599-6022997491
Cites: JAMA. 1986 Jul 4;256(1):413520034
Cites: Lancet. 1987 Jan 17;1(8525):160-12879994
Cites: JAMA. 1987 Feb 6;257(5):635-93795445
Cites: JAMA. 1987 Feb 6;257(5):631-43467076
Cites: Lancet. 1986 Sep 27;2(8509):707-92876184
Comment In: CMAJ. 1990 Dec 1;143(11):1153-52121326
PubMed ID
2114210 View in PubMed
Less detail
Source
Nurs Que. 1991 Mar-Apr;11(2):35
Publication Type
Article
Source
Nurs Que. 1991 Mar-Apr;11(2):35
Language
French
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - economics - therapy
Canada
Humans
Social Support
PubMed ID
2027600 View in PubMed
Less detail

6 records – page 1 of 1.